The company's patented MANF drug could be worth billions. Recentyly announced "orphan indication" for Retinitis Pigmentosa. A second "orphan indication" will be released soon.
Buy a few shares under a dime. Due diligence.
Follow the company on Twitter: @AmarantusBio .... 8,477 followers.
One of the co-founders of Amgen and the former head of M & A at Novartis are two of the members of the company's advisory board.
Zack's analyst, Jason Napadano, has a "buy rating" on AMBS with a price target of .20 or about 400% upside.
Read the recent Yahoo news.
Buy a few shares and hold them for a year.